Bioventus (BVS) Restructuring Costs (2020 - 2026)

Bioventus' (BVS) quarterly Restructuring Costs came in at $454000.0 in Q1 2026, up 973.08% on a QoQ basis from -$52000.0 in Q4 2024.

Bioventus (BVS) Restructuring Costs (2020 - 2026) Analysis & Trends

Bioventus (BVS) has 6 years of Restructuring Costs data on file, last reported at $454000.0 in Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to $454000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $402000.0 (up 873.08% YoY) and the FY2025 annual result came in at $2.2 million, up 4398.08% from the prior year.
Restructuring Costs climbed to $454000.0 in Q1 2026, from -$52000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $4.6 million in Q4 2022 to a low of -$71000.0 in Q4 2023.
A 4-year average of $802100.0 and a median of $514500.0 in 2022 frame the typical range for Restructuring Costs.
Annual changes were most pronounced in 2022 — Restructuring Costs surged 570.54% — and 2023, when it plunged 104.52%.
Tracing BVS's Restructuring Costs over 4 years: stood at $4.6 million in 2022, then slumped by 101.54% to -$71000.0 in 2023, then gained by 26.76% to -$52000.0 in 2024, then soared by 973.08% to $454000.0 in 2026.
The last three Restructuring Costs figures came in at $454000.0 (Q1 2026), -$52000.0 (Q4 2024), and -$71000.0 (Q4 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	200.08 Bn	194.48 Bn	7.27 Bn
2	Stryker	129.71 Bn	126.23 Bn	4.50 Bn
3	Medtronic	120.07 Bn	110.85 Bn	6.41 Bn
4	Boston Scientific	74.08 Bn	73.54 Bn	3.85 Bn
5	Edwards Lifesciences	52.68 Bn	48.43 Bn	1.35 Bn
6	Dexcom	34.51 Bn	32.56 Bn	830.00 Mn
7	GE HealthCare Technologies	34.03 Bn	31.92 Bn	2.18 Bn
8	Koninklijke Philips	26.51 Bn	23.19 Bn	4.55 Bn
9	Steris	23.20 Bn	22.72 Bn	684.20 Mn
10	Bioventus	982.75 Mn	953.29 Mn	105.67 Mn

Download Data